Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583197 | 0.89 | AKR1B1 (0.45) | AKR1B1MAP3K14P2RX7BACE1APP | |
| SCHEMBL6605188 | 0.75 | AKR1B1 (0.42) | AKR1B1MAP3K14PTGS2PTGS1 | |
| SCHEMBL6580397 | 0.75 | AKR1B1 (0.42) | AKR1B1MAP3K14PTGS2PTGS1 | |
| SCHEMBL6605186 | 0.75 | AKR1B1 (0.42) | AKR1B1MAP3K14PTGS2PTGS1 | |
| SCHEMBL6580389 | 0.75 | PDE7A (0.36) | MAP3K14BACE1PTGS2PTGS1NPC1 | |
| SCHEMBL11367364 | 0.74 | MAP3K14 (0.47) | AKR1B1MAP3K14BACE1APPNPC1 | |
| SCHEMBL6606181 | 0.70 | AKR1B1 (0.33) | AKR1B1MAP3K14 | |
| SCHEMBL6603942 | 0.70 | AKR1B1 (0.33) | AKR1B1MAP3K14 | |
| SCHEMBL5399566 | 0.68 | MEN1 (0.36) | AKR1B1NPC1L3MBTL1 | |
| SCHEMBL5399558 | 0.68 | MEN1 (0.36) | AKR1B1NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012140-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
| US-4305877-A | ALDOSE REDUCTASE ENZYME INHIBITOR FOR TREATMENT OF CHRONIC DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4267342-A | INHIBITORS OF OXIDOREDUCTASE ENZYMES; NERVOUS SYSTEM DISORDERS AND VISION DEFECTS CAUSED BY DIABETES | PFIZER INC. (US) | 1981-05-12 | — | — | US | disclosed |
| US-4200642-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | AKR1B1 1664/4885MAP3K14 3472/4885P2RX7 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.